Takis announces that the company was selected and awarded by "Città Metropolitana di Roma" to hire a FTE aiming at developing new products. The selection took place among dozen of companies in Roman area.
Dr Laura Luberto will conduct an ambitious project aiming at developing two products, specifically:
1) a Immunoistchemistry kit to select cancer patients who will benefit of our RevErTremAb therapy;
2) a System to isolate Circulating Tumor Cells in peripheral blood.
"We are proud to have been selected for this program. Takis is fully committed to develop new Cancer Therapies, diagnostic kits and at the same time contribute to employ high specialized scientists in our region, like Laura" - says Luigi Aurisicchio, CEO/CSO at Takis Biotech. "We are sure that our ReverTreTest companion kit will be instrumental for the full development of our anti-HER3 program".